Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) – Analysts at William Blair lifted their Q4 2023 EPS estimates for Cellebrite DI in a note issued to investors on Tuesday, November 14th. William Blair analyst J. Ho now anticipates that the company will earn $0.03 per share for the quarter, up from their prior estimate of ($0.09). The consensus estimate for Cellebrite DI’s current full-year earnings is $0.23 per share. William Blair also issued estimates for Cellebrite DI’s FY2024 earnings at $0.14 EPS.
Several other analysts have also recently issued reports on CLBT. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Cellebrite DI in a research report on Wednesday, August 30th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Cellebrite DI from $6.50 to $9.00 in a research report on Wednesday, August 9th.
Cellebrite DI Price Performance
Shares of CLBT stock opened at $8.00 on Friday. The firm has a market cap of $1.58 billion, a PE ratio of -25.81, a price-to-earnings-growth ratio of 0.78 and a beta of 1.31. The company has a 50-day moving average of $7.31 and a two-hundred day moving average of $6.95. Cellebrite DI has a 1-year low of $3.96 and a 1-year high of $8.38.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last announced its earnings results on Tuesday, November 14th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.08. The company had revenue of $84.20 million during the quarter, compared to analyst estimates of $82.13 million. Cellebrite DI had a negative net margin of 19.40% and a positive return on equity of 115.74%. Cellebrite DI’s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.01) earnings per share.
Institutional Trading of Cellebrite DI
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG acquired a new stake in Cellebrite DI during the first quarter worth approximately $26,000. New York State Common Retirement Fund acquired a new stake in Cellebrite DI during the first quarter worth approximately $35,000. Lazard Asset Management LLC purchased a new position in shares of Cellebrite DI during the fourth quarter worth approximately $32,000. Steward Partners Investment Advisory LLC grew its position in shares of Cellebrite DI by 81.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,784 shares of the company’s stock worth $34,000 after acquiring an additional 3,494 shares during the last quarter. Finally, State of Tennessee Treasury Department acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $48,000. Institutional investors and hedge funds own 21.80% of the company’s stock.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.
- Five stocks we like better than Cellebrite DI
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 large caps with red hot RSIs with upside
- What is a Bond Market Holiday? How to Invest and Trade
- Johnson Controls International: Nothing but upside for investors
- Investing in Commodities: What Are They? How to Invest in Them
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.